Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Ligand Pharmaceuticals Incorporated

Biotech Giants: A Decade of SG&A Cost Strategies

__timestampAlpine Immune Sciences, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 2014228770922570000
Thursday, January 1, 2015684400024378000
Friday, January 1, 2016858600026621000
Sunday, January 1, 2017607900028653000
Monday, January 1, 2018836200037734000
Tuesday, January 1, 2019946700041884000
Wednesday, January 1, 20201089900064435000
Friday, January 1, 20211456000057483000
Saturday, January 1, 20221796800070062000
Sunday, January 1, 20232222200052790000
Loading chart...

In pursuit of knowledge

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Alpine Immune Sciences, Inc. and Ligand Pharmaceuticals Incorporated, two prominent players, have shown contrasting strategies over the past decade. From 2014 to 2023, Alpine Immune Sciences saw a nearly tenfold increase in SG&A expenses, peaking at $22 million in 2023. This reflects a strategic investment in growth and expansion. In contrast, Ligand Pharmaceuticals maintained a more stable trajectory, with expenses fluctuating between $23 million and $70 million, indicating a focus on consistent operational efficiency. Notably, Ligand's expenses surged by 185% from 2014 to 2022, before a slight dip in 2023. This comparison highlights the diverse approaches companies can take in optimizing costs, balancing between aggressive growth and steady management.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025